Cyproheptadine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2YHB6175DO, chemically known as 5-(1-methylpiperidylidene-4)-5h-dibenzo(a,d)cyclopheptene but generally known as cyproheptadine, which bears US NIH Compound Identifier 2913. European Medicines Agency schedules Cyproheptadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06875MIG. The term CYPROHEPTADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules cyproheptadine in its Anatomical Therapeutic Chemical (ATC) Classification. CYPROHEPTADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cyproheptadine under HS 29333999 and SITC 51574. As of Q4 2014, CYPROHEPTADINE remains the US FDA Preferred Term for this commodity. Cyproheptadine bears US NLM identifiers UMLS ID C0010620 and NCI Concept Code C61695. SMILES: N1(CC/C(=C2/C3C(C=CC4C2CCCC4)CCCC3)CC1)C.